Establishment and validation of a recurrence risk model in early-stage tongue squamous cell carcinoma patients incorporating immune-inflammatory biomarkers and clinicopathological parameters

This predictive model, integrating immuno-inflammatory markers and clinicopathological features, exhibits excellent predictive performance for recurrence risk in early-stage STCC and offers substantial clinical utility.